Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.
Brun S, Bestion E, Raymond E, Bassissi F, Jilkova ZM, Mezouar S, Rachid M, Novello M, Tracz J, Hamaï A, Lalmanach G, Vanderlynden L, Legouffe R, Stauber J, Schubert T, Plach MG, Courcambeck J, Drouot C, Jacquemot G, Serdjebi C, Roth G, Baudoin JP, Ansaldi C, Decaens T, Halfon P. Brun S, et al. Among authors: rachid m. Autophagy. 2022 Mar;18(3):678-694. doi: 10.1080/15548627.2021.1988357. Epub 2021 Nov 5. Autophagy. 2022. PMID: 34740311 Free PMC article.
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
Bestion E, Jilkova ZM, Mège JL, Novello M, Kurma K, Pour STA, Lalmanach G, Vanderlynden L, Fizanne L, Bassissi F, Rachid M, Tracz J, Boursier J, Courcambeck J, Serdjebi C, Ansaldi C, Decaens T, Halfon P, Brun S. Bestion E, et al. Among authors: rachid m. Ther Adv Chronic Dis. 2020 Jul 16;11:2040622320942042. doi: 10.1177/2040622320942042. eCollection 2020. Ther Adv Chronic Dis. 2020. PMID: 32728410 Free PMC article.
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E. Harding JJ, et al. Among authors: rachid m. Liver Cancer. 2022 Feb 15;11(3):268-277. doi: 10.1159/000522418. eCollection 2022 Jun. Liver Cancer. 2022. PMID: 35949290 Free PMC article.
Phase I study of veliparib in combination with gemcitabine.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Stoller R, et al. Among authors: rachid m. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2. Cancer Chemother Pharmacol. 2017. PMID: 28770300 Free PMC article. Clinical Trial.
Targeting p53-dependent stem cell loss for intestinal chemoprotection.
Leibowitz BJ, Yang L, Wei L, Buchanan ME, Rachid M, Parise RA, Beumer JH, Eiseman JL, Schoen RE, Zhang L, Yu J. Leibowitz BJ, et al. Among authors: rachid m. Sci Transl Med. 2018 Feb 7;10(427):eaam7610. doi: 10.1126/scitranslmed.aam7610. Sci Transl Med. 2018. PMID: 29437148 Free PMC article.
Flipping the script: The benefits of inverted classrooms in oncology education.
Dahbi Z, Fareh M, Elomri G, Rachid M, Daher B, Taali L, Ghaddou Y. Dahbi Z, et al. Among authors: rachid m. J Educ Health Promot. 2024 Oct 28;13:414. doi: 10.4103/jehp.jehp_21_24. eCollection 2024. J Educ Health Promot. 2024. PMID: 39703639 Free PMC article. No abstract available.
244 results